GLP1R and familial dilated cardiomyopathy: Three new targets for antidiabetic agents, glucagon-like peptide 1 receptor (GLP1R), dipeptidylpeptidase 4 (DPP4), and sodium-glucose cotransporter 2 (SGLT2), have gained popularity because of their crucial role in DCM [20].